These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 35742953)

  • 21. P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth.
    Gang X; Yang Y; Zhong J; Jiang K; Pan Y; Karnes RJ; Zhang J; Xu W; Wang G; Huang H
    Oncotarget; 2016 Mar; 7(12):15135-49. PubMed ID: 26934656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epstein-Barr Virus-Encoded Latent Membrane Protein 1 and B-Cell Growth Transformation Induce Lipogenesis through Fatty Acid Synthase.
    Hulse M; Johnson SM; Boyle S; Caruso LB; Tempera I
    J Virol; 2021 Jan; 95(4):. PubMed ID: 33208446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of fatty acid synthase is regulated by PGC‑1α and contributes to increased cell proliferation.
    Yun SH; Shin SW; Park JI
    Oncol Rep; 2017 Dec; 38(6):3497-3506. PubMed ID: 29130104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression.
    Ventura R; Mordec K; Waszczuk J; Wang Z; Lai J; Fridlib M; Buckley D; Kemble G; Heuer TS
    EBioMedicine; 2015 Aug; 2(8):808-24. PubMed ID: 26425687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of fatty acid synthase suppresses neovascularization via regulating the expression of VEGF-A in glioma.
    Zhou Y; Jin G; Mi R; Zhang J; Zhang J; Xu H; Cheng S; Zhang Y; Song W; Liu F
    J Cancer Res Clin Oncol; 2016 Dec; 142(12):2447-2459. PubMed ID: 27601165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans.
    Li L; Che L; Tharp KM; Park HM; Pilo MG; Cao D; Cigliano A; Latte G; Xu Z; Ribback S; Dombrowski F; Evert M; Gores GJ; Stahl A; Calvisi DF; Chen X
    Hepatology; 2016 Jun; 63(6):1900-13. PubMed ID: 26910791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer.
    Zaytseva YY; Rychahou PG; Le AT; Scott TL; Flight RM; Kim JT; Harris J; Liu J; Wang C; Morris AJ; Sivakumaran TA; Fan T; Moseley H; Gao T; Lee EY; Weiss HL; Heuer TS; Kemble G; Evers M
    Oncotarget; 2018 May; 9(37):24787-24800. PubMed ID: 29872506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis.
    Goswami S; Sharma-Walia N
    Oncotarget; 2016 Sep; 7(37):58953-58974. PubMed ID: 27270654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eukaryotic initiation factor 6 repression mitigates atherosclerosis progression by inhibiting macrophages expressing Fasn.
    Chen Y; Wang Z; Xian X; Zhuang Y; Chang J; Zhan X; Han X; Chen Q; Yang Z; Chen R
    IUBMB Life; 2023 May; 75(5):440-452. PubMed ID: 36469534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The "HER2-PI3K/Akt-FASN Axis" regulated malignant phenotype of colorectal cancer cells.
    Li N; Bu X; Wu P; Wu P; Huang P
    Lipids; 2012 Apr; 47(4):403-11. PubMed ID: 22218925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fatty Acid Synthase Is the Key Regulator of Fatty Acid Metabolism and Is Related to Immunotherapy in Bladder Cancer.
    Xiong Q; Feng D; Wang Z; Ying Y; Xu C; Wei Q; Zeng S; Yang L
    Front Immunol; 2022; 13():836939. PubMed ID: 35392075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fatty acid synthase is a key target in multiple essential tumor functions of prostate cancer: uptake of radiolabeled acetate as a predictor of the targeted therapy outcome.
    Yoshii Y; Furukawa T; Oyama N; Hasegawa Y; Kiyono Y; Nishii R; Waki A; Tsuji AB; Sogawa C; Wakizaka H; Fukumura T; Yoshii H; Fujibayashi Y; Lewis JS; Saga T
    PLoS One; 2013; 8(5):e64570. PubMed ID: 23741342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting fatty acid synthase sensitizes human nasopharyngeal carcinoma cells to radiation
    Chen J; Zhang F; Ren X; Wang Y; Huang W; Zhang J; Cui Y
    Cancer Biol Med; 2020 Aug; 17(3):740-752. PubMed ID: 32944403
    [No Abstract]   [Full Text] [Related]  

  • 34. Global gene deregulations in FASN silenced retinoblastoma cancer cells: molecular and clinico-pathological correlations.
    Sangeetha M; Deepa PR; Rishi P; Khetan V; Krishnakumar S
    J Cell Biochem; 2015 Nov; 116(11):2676-94. PubMed ID: 25958981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Triclosan down-regulates fatty acid synthase through microRNAs in HepG2 cells.
    Sun D; Zhao T; Long K; Wu M; Zhang Z
    Eur J Pharmacol; 2021 Sep; 907():174261. PubMed ID: 34144025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Body mass index and risk of colorectal cancer according to fatty acid synthase expression in the nurses' health study.
    Kuchiba A; Morikawa T; Yamauchi M; Imamura Y; Liao X; Chan AT; Meyerhardt JA; Giovannucci E; Fuchs CS; Ogino S
    J Natl Cancer Inst; 2012 Mar; 104(5):415-20. PubMed ID: 22312135
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Jafari N; Drury J; Morris AJ; Onono FO; Stevens PD; Gao T; Liu J; Wang C; Lee EY; Weiss HL; Evers BM; Zaytseva YY
    Mol Cancer Res; 2019 Jan; 17(1):140-152. PubMed ID: 30154249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer.
    Migita T; Ruiz S; Fornari A; Fiorentino M; Priolo C; Zadra G; Inazuka F; Grisanzio C; Palescandolo E; Shin E; Fiore C; Xie W; Kung AL; Febbo PG; Subramanian A; Mucci L; Ma J; Signoretti S; Stampfer M; Hahn WC; Finn S; Loda M
    J Natl Cancer Inst; 2009 Apr; 101(7):519-32. PubMed ID: 19318631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Her-2-directed systemic delivery of fatty acid synthase (FASN) siRNA with novel liposomal carrier systems in the breast cancer mouse model.
    Khan A; Aljarbou AN; Khan S; Khan MA
    J Drug Target; 2022 Jul; 30(6):634-645. PubMed ID: 35112640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PdpaMn inhibits fatty acid synthase-mediated glycolysis by down-regulating PI3K/Akt signaling pathway in breast cancer.
    Okrah EA; Wang Q; Fu H; Chen Q; Gao J
    Anticancer Drugs; 2020 Nov; 31(10):1046-1056. PubMed ID: 32649369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.